Related Experiment Video

Updated: Aug 18, 2026

Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

Clinical and economic lessons from studies of coronary thrombolysis

D B Mark1

  • 1Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.

Journal of Vascular and Interventional Radiology : JVIR
|November 1, 1995
PubMed

Insights

Coronary reperfusion therapy, particularly with tissue plasminogen activator (t-PA), significantly saves lives in acute myocardial infarction patients compared to older treatments. This advanced therapy offers improved blood flow restoration and is cost-effective for saving lives.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Thrombosis Research

Background:

  • Acute myocardial infarction (AMI) is often caused by atherosclerotic plaque rupture and thrombosis.
  • Arterial occlusion in AMI leads to myocardial necrosis, which can be halted by early reperfusion.
  • Reperfusion therapy preserves myocardial function and reduces mortality.

Purpose of the Study:

  • To evaluate the effectiveness of thrombolytic therapy in acute myocardial infarction.
  • To compare the efficacy and cost-effectiveness of tissue plasminogen activator (t-PA) versus streptokinase.
  • To assess the economic viability of new reperfusion technologies in managed care settings.

Main Methods:

  • Pooled analysis of data from nearly 60,000 patients undergoing reperfusion therapy.
  • Comparison of outcomes between streptokinase and accelerated dosing regimens of t-PA.
  • Economic analysis of cost-effectiveness, specifically cost per life-year added.

Main Results:

  • Thrombolysis significantly improves survival compared to no reperfusion.
  • Tissue plasminogen activator (t-PA) demonstrates superior efficacy, saving one additional life per hundred patients treated compared to streptokinase.
  • t-PA offers improved early and complete restoration of infarct artery blood flow.
  • Economic analysis indicates t-PA is cost-effective at approximately $33,000 per life-year added relative to streptokinase.

Conclusions:

  • Early reperfusion therapy is crucial for managing acute myocardial infarction.
  • Tissue plasminogen activator (t-PA) represents a significant advancement in AMI treatment, offering improved survival benefits.
  • New medical technologies must demonstrate clear medical benefits relative to their costs, especially within cost-containment healthcare systems.

More Related Videos

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

Related Concept Videos

Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...